ALX Oncology Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALXO research report →
About the company
ALX Oncology Holdings Inc. , a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
- CEO
- Jason Lettmann
- IPO
- 2020
- Employees
- 43
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $278.55M
- P/E
- -1.25
- P/S
- 0.00
- P/B
- 0.74
- EV/EBITDA
- -2.90
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -124.06%
- ROIC
- -55.81%
- Revenue
- $0 · 0.00%
- Net Income
- $-101,695,000 · 24.59%
- EPS
- $-1.90 · 26.36%
- Op Income
- $-104,021,000
- FCF YoY
- 31.06%
- 52W High
- $2.66
- 52W Low
- $0.44
- 50D MA
- $1.80
- 200D MA
- $1.72
- Beta
- 0.45
- Avg Volume
- 1.43M
Get TickerSpark's AI analysis on ALXO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 16, 26 | Knight Jeff E. | other | 800,000 |
| Apr 16, 26 | Klencke Barbara | other | 100,000 |
| Apr 13, 26 | Knight Jeff E. | other | 0 |
| Mar 19, 26 | Lettmann Jason | sell | 12,311 |
| Mar 19, 26 | Pinto Shelly | sell | 903 |
| Mar 3, 26 | Klencke Barbara | other | 700,000 |
| Feb 25, 26 | Klencke Barbara | other | 0 |
| Feb 25, 26 | Klencke Barbara | other | 40,400 |
| Feb 25, 26 | Klencke Barbara | other | 300,000 |
| Feb 25, 26 | Klencke Barbara | other | 100,000 |
Our ALXO coverage
Recent articles, reports, and earnings notes.
No research on ALXO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALXO report →Similar companies
Peers in the same neighborhood.